MAdCAM TARGETED IMMUNOTOLERANCE
AssigneePandion Therapeutics, Inc.
InventorsNathan Higginson-Scott, Joanne L. Viney, Kevin Lewis Otipoby, Jyothsna Visweswaraiah, Salvatore Alioto, Lindsay J. Edwards, Erik Sampson, Jacob Glanville, David Maurer, Sarah Ives, Christina Pettus, Lauren Schwimmer
Life of this patent
Estimating the term…
Abstract
Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.
Claims29
1-116. (canceled)
An antibody that binds to MAdCAM, wherein the antibody comprises one or more sequence as provided in Table 6 or Table 7.
The antibody of 126, wherein the IL-2 mutein is fused or linked to a Fc peptide.
A polypeptide having a formula of:
- Ab-ConstantDomain-LinkerA-IL2Mutein-LinkerB-FcRegion,
- wherein:
- Ab is a heavy chain variable region of the antibody of claim 2;
- ConstantDomain is an IgG constant domain;
- Linker A is a peptide linker;
- IL2Mutein is an IL-2 mutein;
- Linker B is a peptide linker;
- and
- FcRegion is a Fc region.
A pharmaceutical composition comprising the antibody of claim 1.
A cell comprising a nucleic acid molecule encoding the antibody of claim 1.
A polypeptide comprising:
- i) a peptide comprising a sequence of SEQ ID NO:
- 90, 91, 92, 93, 94, 170, 359, 360, 361, 362, 363, 135, 381, 382, 383, 384, or 385, or any variant of the foregoing;
- ii) a peptide comprising a sequence of SEQ ID NOs:
- 90, 91, 92, 93, 87, and 94, or any variant of any of the foregoing;
- iii) a peptide comprising a sequence of SEQ ID NOs:
- 135, 381, 382, 383, 384, and 385, or any variant of any of the foregoing;
- iv) a peptide comprising a sequence of SEQ ID NOs:
- 359, 170, 360, 361, 362, and 363, or any variant of any of the foregoing;
- v) a peptide comprising a sequence of SEQ ID NOs:
- 90, 91, and 92, or any variant of any of the foregoing;
- vi) a peptide comprising a sequence of SEQ ID NOs:
- 93, 87, and 94, or any variant of any of the foregoing;
- vii) a peptide comprising a sequence of SEQ ID NOs:
- 135, 381, and 382 or any variant of any of the foregoing;
- viii) a peptide comprising a sequence of SEQ ID NOs:
- 383, 384, and 385, or any variant of any of the foregoing;
- ix) a peptide comprising a sequence of SEQ ID NOs:
- 359, 170, and 360, or any variant of any of the foregoing;
- or
- x) a peptide comprising a sequence of SEQ ID NOs:
- 361, 362, and 363, or any variant of any of the foregoing.
Dependencies are inferred from the claim text.